Bayer will present three new prespecified subgroup analyses from the pivotal Phase III FINEARTS-HF cardiovascular outcomes trial investigating KERENDI ...

BACKGROUND: The ability to predict recovery of left ventricular ejection fraction (LVEF) in response to guideline-directed therapy among patients with nonischemic cardiomyopathy is desired. We sought ...

Individuals with ICM typically have a left ventricular ejection fraction ... (medical therapy alone) is the safest and most ...

There’s no “silver bullet” for this problem, which is largely driven by clinical inertia, but some efforts are chipping away ...

multi-center pivotal clinical trial for the treatment of heart failure of reduced ejection fraction (HFrEF). The CardiAMP HF Trial is assessing the safety and effectiveness of the CardiAMP ® Cell ...

For patients with heart failure and preserved left ventricular function, where evidence-based treatment options are limited, improvement was slower. "These results show the great need for research ...

However, the relationship between the TyG index and heart failure with preserved ejection fraction in patients with essential hypertension has not yet been explored. To fill this knowledge gap, ...

The following is a summary of “Heterogeneity in the Effect of Early Goal-Directed Therapy for Septic Shock: A Secondary Analysis of Two Multicenter International Trials,” published in the October 2024 ...

The experimental therapy uses a therapeutic monoclonal antibody engineered by Deb and his team. This targeted drug therapy is designed to mimic human antibodies and inhibit the activity of ENPP1 ...

An experimental therapeutic monoclonal antibody therapy could ... the potential to enhance heart repair following a heart attack, preventing the onset of heart failure. Cardiovascular disease ...